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ABSTRACT
Small nucleolar RNAs (snoRNAs) are dynamically regulated in different tissues 
and affected in disease. SnoRNAs are processed further to stable smaller RNAs. 
We sequenced the small RNA transcriptome of prostate cancer (PCa) at different 
PCa stages and generated a quantified catalogue of 3927 small non-coding RNAs 
(sncRNAs) detected in normal and malignant prostate tissue. From these, only 1524 
are microRNAs. The remaining 2401 sncRNAs represent stable sncRNAs species that 
originate from snoRNA, tRNA and other sncRNAs. We show that snoRNA-derived RNAs 
(sdRNAs) display stronger differential expression than microRNAs and are massively 
upregulated in PCa. SdRNAs account for at least one third of all small RNAs with 
expression changes in tumor compared to normal adjacent tissue. Multiple sdRNAs can 
be produced from one snoRNA in a manner related to the conservation of structural 
snoRNA motifs. Q-PCR analysis in an independent patient cohort (n=106) confirmed 
the processing patterns of selected snoRNAs (SNORD44, SNORD78, SNORD74 and 
SNORD81) and the cancer-associated up-regulation of their sdRNAs observed in 
sequencing data. Importantly, expression of SNORD78 and its sdRNA is significantly 
higher in a subset of patients that developed metastatic disease demonstrating that 
snoRNA and sdRNAs may present as novel diagnostic and/or prognostic biomarkers 
for PCa. 
INTRODUCTION
Malignant transformation and cancer progression 
cause changes in the expression and function of 
microRNAs (miRNAs) [1, 2]. However, the effects 
of these processes on other small non-coding RNAs 
(sncRNAs) are less understood. Recently, we 
demonstrated the abundance and differential expression 
of small nucleolar RNA-derived RNAs (sdRNAs) in the 
small transcriptome of prostate cancer (PCa) [3]. It is 
generally accepted that small nucleolar RNAs (snoRNAs) 
are housekeeping, protein-noncoding molecules that 
associate with specific sets of proteins to maintain proper 
ribosomal maturation in the nucleolus. 
Still, several reports show that snoRNAs have 
tissue-specific expression [4, 5], and may present as 
novel cancer biomarkers. For example, the H/ACA-
box snoRNA SNORA42 is commonly overexpressed in 
non-small cell lung cancer (NSCLC) and its expression 
is significantly inversely correlated with survival [6, 7]. 
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Similarly, the levels of C/D-box snoRNAs SNORD33, 
SNORD66 and SNORD76 are significantly elevated in 
plasma from NSCLC patients compared with cancer-free 
controls and can provide potential biomarkers for early 
detection [8]. In chronic lymphocytic leukemia (CLL), 
heterogeneous snoRNA expression patterns discriminate 
major CLL subgroups and can stratify patients in different 
prognostic groups [9], while in multiple myeloma snoRNA 
expression patterns are associated with distinct molecular 
subtypes of the disease [10].
Furthermore, resent research demonstrates that the 
molecular alterations of snoRNA are functionally linked to 
basic cellular processes associated with cancer proposing 
either tumor suppressor or oncogene role for different 
snoRNAs. In NSCLC, SNORA42 acts as a putative 
oncogene. Its overexpression enhances cell proliferation 
and growth in bronchial epithelium and cancer cells, while 
its knockdown in NSCLC cells inhibits colony forming 
[7]. In acute promyelocytic leukemia, the SNORD112–114 
is specifically activated in a subset of patients and may 
influence cell growth through a negative regulation of 
the cell cycle and the Rb pathway [11]. On the contrary, 
in peripheral T-cell lymphoma, over-expression of the 
candidate prognostic marker SNORD71 (HBII-239) is 
associated with favorable outcome [12]. The C/D box 
snoRNA SNORD50, a translocation partner of BCL6 in 
B-cell lymphoma [13], is a candidate tumor suppressor 
significantly associated with clinically relevant prostate 
[14] and breast [15] cancer. In hepatocellular carcinoma 
(HCC), SNORD113-1 has been identified as a tumor 
suppressor [16]. Down-regulation of this snoRNA is 
associated with decreased survival of HCC patients, while 
reconstitution of its expression suppresses tumorigenesis 
in vitro and in vivo. In glioblastoma, decreased expression 
of the GAS5 encoded SNORD76 is associated with an 
aggressive phenotype [17]. Ectopic expression of this 
tumor suppressor snoRNA inhibits tumorigenicity by 
arresting cancer cells in S phase in vitro and inhibits 
orthotopic tumor growth in vivo. In breast cancer and head 
and neck squamous cell carcinoma the low expression of 
another GAS5 encoded snoRNA, SNORD44, correlates 
with markers of aggressive pathology and poor prognosis 
[18, 19]. 
At present, little is known about the pathways of 
snoRNA turnover. Apparently, snoRNAs are further 
processed to sdRNAs in a vast variety of organisms [20]. 
It is yet unclear whether sdRNAs are novel functional 
entities or footprint-products of snoRNA downstream 
processing shielded from degradation by snoRNA-
interacting proteins. A miRNA-like activity has been 
proposed for sdRNAs derived from H/ACA-box snoRNAs 
(H/ACA-sdRNAs) based on their apparent size of 20-24 nt 
equivalent to miRNAs, the ability to promote repression 
of complementary targets in vitro, and the association with 
Dicer and AGO complexes [21-27]. In contrast, a bimodal 
size distribution of 17-20 nt and 27-30 nt has been reported 
for sdRNAs derived from C/D-box snoRNAs (C/D-
sdRNAs) [3, 22, 23]. C/D-sdRNAs are not efficiently 
incorporated in AGO2 suggesting a different function for 
this type of sdRNAs [28]. In addition, it has been reported 
that the highly abundant in brain ‘orphan’ snoRNAs, 
SNORD115 and SNORD116, are processed into larger 
sdRNAs (34-73 nt) that complex with spliceosomal 
proteins and may regulate the alternative splicing of target 
mRNAs [29, 30]. Association of C/D-box snoRNAs with 
novel RNPs and involvement in alternative splicing has 
been previously observed in mice for the brain specific 
MbII-52 [31]. Interestingly, both MbII-52 and its human 
ortholog SNORD115 produce larger sdRNAs (34-73 
nt). Similar observation has also been made for sdRNA 
regions of SNORD88C, which can influence the alternative 
splicing of FGFR3 pre-mRNA [32]. At the same time, 
studies in Drosophila sp. and in human cells show that 
snoRNAs are strongly enriched in the nuclear fractions of 
chromatin-associated RNA and possibly involved in the 
maintenance of open chromatin structure [33].
Here, we report the deep sequencing of patient-
derived samples from normal prostate, and PCa in 
different disease stages, which reveals sdRNA production 
from the vast majority of known human snoRNAs. At least 
78 of the detected sdRNAs demonstrate strong differential 
expression in cancer. Furthermore, the expression of some 
sdRNAs and their precursors is associated with clinical 
progression and metastatic occurrence. 
RESULTS
Library preparation and sequencing
We generated 10 sncRNA libraries from normal 
adjacent prostate (NAP), benign prostate hyperplasia 
(BPH), different stages of PCa, and metastatic lymph 
node (LN) prepared from fresh-frozen patient material 
(FF) (Supplementary Table 1). To estimate the influence 
of sample storage on sncRNA abundance and stability, we 
prepared a replicate library from formalin-fixed, paraffin-
embedded tissue (FFPE) from tumor samples used for 
one of the fresh-frozen libraries (group 3). All sequencing 
reactions yielded approximately 14 million raw reads 
each (13,468,284 to 15,393,670) with the FFPE library 
producing the highest raw read number (Figure 1a). 
Annotation of the sncRNA transcriptome 
The correct mapping of sncRNA reads is challenged 
by the fact that predominant isoforms of miRNAs 
and other sncRNAs such as snoRNAs may vary from 
the mature sequences annotated in public databases. 
Differences can be caused by alternative 3’-end 
modifications [34] or alternative 5’-/3’-end positions of 
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the detected sncRNA. Additionally, the length of mature 
sncRNA transcripts can be ambiguously annotated in 
different public databases. To map as many sequence 
reads as possible, we constructed a custom small non-
coding RNA database (sncRNAdb) that consists of 2271 
unique small non-coding RNA species corresponding to 
2356 unique genomic loci (Supplementary Figure 1 and 
Supplementary File 1).
Mapping to sncRNAdb resulted in the detection of 
a total of 1637 unique sncRNAs expressed across any of 
the 11 libraries with an average of 1229 per library. 70% 
to 84% of the reads generated from fresh-frozen samples 
and only 52% of the reads generated from FFPE could be 
annotated by sncRNAdb (Figure 1a and Supplementary 
Table 2). The majority of annotated reads mapped to 873 
pre-miRNAs (85.5 - 95.6%), 385 tRNAs (1.89 - 7.4%), 
228 C/D-box snoRNAs (0.3 - 1.9%), and 91 H/ACA-box 
snoRNAs (0.0 - 0.1%) (Figure 1b, 1c and Supplementary 
Tables 2 and 3). 
Interestingly, in PCa samples we detected up to 
27% more C/D-box and up to 52% more H/ACA-box 
snoRNAs compared to NAP or BPH. Furthermore, total 
snoRNA read-counts were increased at least two-fold, 
indicating possible activation of snoRNA-gene expression 
in response to malignant transformation. In contrast, the 
number of detected miRNAs remained relatively stable 
and the total miRNA read-counts changed by no more 
than 19% (min. 9,202,300, max. 11,367,682) (Figure 1c, 
Supplementary Figure 2 and Supplementary Tables 3 and 
4). 
We also examined the read-length associated with 
different types of sncRNAs. As expected, miRNA reads 
had a narrow size distribution between 21 and 23 nt in 
all libraries. Similar size range was observed for snRNA- 
and scaRNA-derived RNAs in fresh-frozen libraries. In 
concordance with our previous results [3], we detected 
a size peak at 23 nt and a plateau between 26-28 nt for 
reads mapping to C/D-box snoRNAs. Interestingly, reads 
mapping to H/ACA snoRNAs and tRNAs demonstrated 
a shift in size distribution between normal and malignant 
Figure 1: Summary of sncRNA sequencing data from PCa patient samples. (a) Number of retrieved raw, extracted, annotated, 
and unique reads generated for each one of the sequencing libraries. (b) Number of detected sncRNA-species per library. (c) Relative 
abundance of different sncRNA-types per library. Read-length distribution in normal (d) and cancer libraries (e) derived from fresh-frozen, 
(f) and FFPE material. Each sncRNA type is represented by different color: miRNA (red), SNORD (dark blue), SNORA (orange), tRNA 
(green), scaRNA (black), rRNA (gray), snRNA (yellow), scRNA (magenta), other miscellaneous RNAs (light blue).
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samples (Figure 1d, 1e and Supplementary Figure 3) 
suggesting cancer-associated alterations in sncRNA 
processing.
Comparison of the sncRNA composition of 
the FFPE library with its fresh-frozen counterpart 
demonstrated that the relative miRNA read-content 
in FFPE decreased 3.9-fold from 92% to 24% of the 
total annotated reads. On the contrary, the number of 
reads mapping to other sncRNA species was strongly 
elevated i.e. sequence read-counts were increased 152-
fold for snRNAs, 12.7-fold for H/ACA-box snoRNAs, 
5.6-fold for tRNAs, and 2.7-fold for C/D-box snoRNAs 
(χ2 test, p < 0.0001 for all tested groups) (Figure 1c, 
Supplementary Figure 2 and Supplementary Table 4). The 
size distribution of read-length in FFPE material was also 
strongly affected for all examined ncRNA groups except 
for miRNAs. (Figure 1e,f and Supplementary Figure 3). 
These observations can be explained with the higher level 
of RNA degradation in FFPE for transcripts longer than 
miRNA [35, 36]. 
Mapping, and annotation of sncRNA-derived 
RNAs (sncdRNAs)
The majority of miRNA reads in small RNA 
sequencing data map to the specific location on their pre-
miRNA corresponding to the mature miRNA. Similarly, 
reads mapping to other sncRNAs, originate from 
specific positions on their precursor rather than being 
randomly derived and can represent specific, biologically 
functional, smaller RNA species, e.g. sdRNAs or tRNA 
fragments (tRFs) [37]. Nevertheless, the assignment of 
RNA-seq sequence-reads to specific sdRNAs or tRFs for 
quantitation purposes is hampered by the lack of proper 
annotation. Furthermore, many sncRNAs produce multiple 
fragments [29, 30] that may overlap each other, which 
further complicates the exact determination of their origin 
loci and a subsequent quantitative analysis.
To correctly determine the boundaries of sdRNAs, 
tRFs and other sncRNA-derived RNAs (sncdRNAs) in our 
dataset and annotate their specific location on the precursor 
sequence, we applied the computational algorithm 
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Figure 2: FlaiMapper results. (a)Total number of detected sncRNA precursors per RNA type and sequencing library. (b) Total number 
of sncdRNAs per precursor type and sequencing library. (c, d, e, f) Different types of sncRNAs produce different number of fragments. (g) 
Relation between the number of fragments produced per precursor RNA and the expression levels of individual fragments. (h) Relation 
between the number of fragments produced per precursor RNA and the expression levels of the most abundant fragment per precursor. 
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Fragment Location Annotation and Identification Mapper 
(FlaiMapper) and evaluated its performance in this data 
set as described [38]. Shortly, FlaiMapper predicted 5’- 
and 3’-miRNA ends were compared with the 5’- and 
3’-end boundaries of corresponding mature miRNAs in 
MiRBase, v17 [39]. 82% of the detected miRNAs had a 
correctly determined 5’-end exactly matching miRBase 
annotation. An additional 11 % had an offset of 1 nt. In 
agreement with previous observations [39], 3’-ends of 
mature miRNAs had higher variability and matched 
miRBase annotations for 45%. From the investigated 
miRNAs additional 33% had 1 nt offset, and 14%, 2 nt 
offset (Supplementary Figure 4). 
Given the high confidence with which FlaiMapper 
identified 5’- and 3’-end boundaries of bona fide miRNAs, 
we performed annotation of all sncdRNAs in our fresh-
frozen libraries. We detected 3927 unique sncdRNAs 
derived from different precursor classes. From these, 1524 
Figure 3: Global expression changes of sncdRNAs in normal and malignant prostate tissue. Upper and middle panels 
present scatterplots comparing the normalized expression values of individual sncdRNA (dots) in each prostate cancer library (PCa) 
during progressing disease to these in the library prepared from normal adjacent prostate tissue (NAP). The expression of sncdRNAs in 
the hormone-refractory, transurethral resection of the prostate (TURP HR) library is also compared to the benign prostate hyperplasia 
(BPH) library since the latest represents the normal counterpart of malignant transurethral resection of the prostate material. Differences 
in sncdRNA expression between biological replicates of Gleason 6 cancers (PCa 6) as well as comparison of a fresh-frozen library (FF) 
with its formalin-fixed, paraffin-embedded (FFPE) counterpart derived from the same patients are presented in the lower panels. Each 
sncdRNA type is presented by a different color. Diagonal lines across each scatterplot represent fold change difference in expression. 
Middle line, crossing the horizontal and vertical axes at 0, no expression change; lines crossing the vertical and horizontal axes at 2, two-
fold expression change; lines crossing the vertical and horizontal axes at 4, four-fold expression change. Cured, no disease relapse after 
radical prostatectomy; rec., recurrent disease, biochemical or metastatic relapse after surgery; LN, metastatic lymph node sample; TERG+, 
TMPRSS2-ERG fusion gene event; TERG-, no TMPRSS2-ERG fusion event; Numbers (6, 7 or 8) after PCa indicate the pathological 
Gleason score of the tumors in the respective group
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originated from miRNAs, 1175 - from tRNAs, 657 – from 
C/D-box snoRNAs, 244 – from H/ACA-box snoRNAs, 
and 327 – from other sncRNA species (Supplementary 
Table 5 and Supplementary File 2). The total number of 
detected unique sncdRNAs was higher than the number of 
detected unique precursor species showing that individual 
sncRNA precursors produce more than one sncdRNA 
(Figure 2a, 2b and Supplementary Figure 5). For example, 
the majority of pre-miRNAs produced one or two miRNAs 
corresponding to the guide and passenger strand. For C/D 
box snoRNAs we detected between 1 and 6 sdRNAs 
originating from the same precursor, with the exception of 
the unusually long SNORD3A, SNORD3B and SNORD3C, 
which give rise to 10 to 13 C/D-sdRNAs. Most H/ACA-
box snoRNAs produced between 1 and 3 sdRNAs, while 
for tRNAs we detected between 1 and 6 tRFs per precursor 
(Figure 2d-2f). Other examined sncRNAs in our libraries 
produced a varying number of fragments ranging from 3 
for the telomerase RNA component to 28 for the small 
nuclear 7SK RNA (Figure 2c; Supplementary Figure 6 and 
7).
We next argued that the expression level of the 
sncRNA-precursor might positively influence the number 
of sncdRNAs detected per sncRNA. We examined the 
distribution of expression values of individual sncdRNAs 
in relation to the number of sncdRNAs derived per 
sncRNA and could not observe a strong dependency 
between the median expression levels of sncdRNAs and 
the total number of sncdRNAs produced per sncRNA. 
We obtained similar results when the expression level of 
the most abundant sncdRNA per precursor was used as 
a surrogate measure of the expression of the precursor 
RNA (Figure 2g, 2h). Based on these results, we can 
conclude that multiple sncdRNAs originating from the 
same sncRNA can be detected independently of their 
(low) expression level or the expression level of their 
precursor. Vice versa, different precursor RNAs can 
produce only one sncdRNAs with very high abundance. 
Hence, it can be assumed that the number and quantity of 
different sncdRNAs do not directly reflect the abundance 
of their precursor but, like miRNAs, are probably also 
influenced by additional aspects of cellular metabolism, 
e.g. association with protein complexes and/or turnover 
rates. 
The size of unique sdRNAs ranged between 15 
and 29 nt (Supplementary Figure 6). However, when 
the expression of individual sdRNAs of the same length 
were accounted, we observed a predominant size of 23 
nt for the majority H/ACA-sdRNAs and a binominal size 
distribution for C/D-sdRNAs with two predominant sizes 
of 22-23 nt and 28 nt (Supplementary Figure 7), which is 
in agreement with our previous findings and other reports 
[3, 22, 23, 40]. C/D-sdRNAs demonstrated a broader size 
distribution, which however could be a reflection of the 
broader size range of their precursors. 
sdRNAs are differentially expressed in prostate 
cancer 
Previously, we observed differential expression 
of sdRNAs between PCa specimens [3]. To examine if 
such changes are a cancer-specific event we compared 
the expression of FlaiMapper defined sncdRNAs 
between normal (NAP and BPH) and malignant tissues 
of progressing disease (PCa, LN, TURP). We detected 
between 34 and 202 sncdRNAs with significant differential 
expression (Table 1, Figure 3, and Supplementary File 3). 
Approximately one third of the differentially expressed 
RNAs in each comparison comprised C/D-sdRNAs 
upregulated in cancer (Figure 3). In contrast, only one 
sdRNA was differentially expressed between non-
malignant samples (NAP and BPH) and only five, between 
biological replicate samples (PCa, Gleason 6, groups 3, 
4, and 10). This suggests that the accumulation of C/D-
sdRNAs is primarily driven by malignant transformation. 
To examine the effect of sample storage on 
fragment abundance we compared the expression of 
sncdRNAs between the FFPE sample and its fresh-frozen 
(FF) counterpart. We limited comparison analyses to 
sncRNAs detected in any of the FF libraries. MiRNAs 
had decreased expression in FFPE compared with 
sdRNAs, tRFs and other sncdRNAs (Table 1, Figure 3 and 
Supplementary Figure 8). Nevertheless, the reduction of 
miRNA expression in FFPE appears to be the result of a 
global decrease in miRNA read-counts compared to read-
counts of other sncdRNAs (Figure 1c) since the relative 
expression of miRNAs correlated strongly between both 
conditions (Pearson ρ = 0.9289) (Supplementary Figure 
8). This was not observed for sdRNAs (Pearson ρ = 0.6557 
for C/D-sdRNAs and 0.3895 for H/ACA-sdRNAs) or 
other sncdRNAs, which have longer precursors and may 
be more susceptible to degradation in FFPE material. 
SdRNAs demonstrate specific global processing 
patterns in prostate tissue
Given the discrete size and specific expression 
of sdRNAs, we examined detected snoRNAs for the 
presence of a common processing pattern. To be able to 
compare with miRNAs, we aligned all snoRNA and pre-
miRNA sequences and visualized the position and relative 
abundance of the corresponding sdRNAs and miRNAs 
(Figure 4, Supplementary file 4 and 5). The majority of 
sdRNAs originated from equivalent locations of their 
precursors. Often, one predominant sdRNA was observed 
per precursor. The position of these predominant sdRNAs 
was not dependent on the total number of smaller species 
detected per precursor sequence, showing a rather uniform 
fragmentation pattern consistent with the precursor-type. 
This is in agreement with previously suggested specific 
snoRNAs processing and accumulation of smaller RNAs 
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observed in cell lines [28, 32]. 
In our patient samples, predominant H/ACA-
sdRNAs originate from either the 5’-arm of the first H/
ACA-snoRNA hairpin (38.5%) or the 3’-arm of the 
second hairpin including the region of the ACA-box (31%) 
(Figure 4b). C/D-box snoRNA produce twice as many 
predominant sdRNAs originating from the 5’-terminus 
that contain a C-box (60.1%) compared to 3’-terminal 
sdRNAs that contain a D-box (30.1%) (Figure 4a). 
Interestingly, individual C/D-sdRNAs with 
highly similar sequences demonstrate almost identical 
fragmentation pattern, which is also dependent on the 
conservation of snoRNA structural features. For example, 
snoRNAs from the highly conserved, multiple gene-copy 
SNORD116 family (HBII-85), which have a degenerated 
C’-box (UGAGUGA) produce four sdRNAs where the 
most abundant one maps to the 5’-region covering the 
C-box. SnoRNAs from the SNORD115 (HBII-52) family 
with conserved C’/D’-boxes produce three sdRNAs, with 
the most abundant ones mapping to the middle-region and 
covering the entire K-loop including the C’/D’-box. In 
contrast, the larger snoRNAs from the SNORD3 family, 
which lack a conserved C-box, produce between 10 and 13 
overlapping sdRNAs with the most predominant mapping 
to the 3’-end. 
SNORD115 and SNORD116 sdRNAs differ in size 
and position from the previously reported highly abundant 
psnoRNAs processed from the orthologous MBII-52 and 
MBII-85 detected by RNase protection assays [29, 30, 
41]. This discrepancy could be explained by the implicit 
methodology differences between sncRNA sequencing and 
RNase protection assays. However, these differences could 
be also caused by tissue-specific sdRNA accumulation 
as previously described for sdRNAs originating from 
SNORD88C (HBII-180C) [32] or by the dependence of 
processing mechanisms on the structural conservation of 
C/D-box snoRNAs. Of note, SNORD115, SNORD116, or 
SNORD88C-originating sdRNAs were detected at low 
abundance in our samples.
Processing and expression of sdRNAs originating 
from GAS5 encoded C/D-box snoRNAs is related 
to the conservation of structural C’/D’-boxes
We investigated whether the fragmentation pattern 
of other C/D-box snoRNA is also dependent on structural 
feature conservation. For this we analyzed the positional 
origin of a highly abundant sdRNA produced from the 3’-
end of SNORD78 [3] and other sdRNAs from the same 
locus. SNORD78 is intronically encoded by the Growth 
Arrest Specific 5 gene (GAS5) together with 9 other C/D-
box snoRNAs [42]. All 10 SNORDs are presumably 
simultaneously transcribed as a GAS5 precursor-transcript, 
which undergoes intron removal and posttranscriptional 
processing. We could detect sdRNAs from all 10 GAS5-
encoded snoRNAs. However, only four (SNORD44, 
SNORD78, SNORD74 and SNORD81) snoRNAs produced 
abundant sdRNAs (Figure 5 and Supplementary Figure 9). 
Interestingly, SNORD74 and SNORD81 produced 
three abundant sdRNAs with similar, relatively low 
expression levels that mapped to the 5’-, 3’-, and middle 
region of the snoRNAs. The 3’- and middle sdRNAs 
overlapped each other and covered the K-loop and the 
conserved canonical C’/D’-box (Figure 5). In contrast, 
SNORD78 and SNORD44, which lack the canonical C’/
D’-box, produced predominantly one 28 nt long sdRNA 
each, mapping to the 3’-arm for SNORD78 (sd78-3’) or the 
5’-arm of SNORD44 (sd44-5’). sd78-3’ and sd44-5’ were 
strongly upregulated in samples prepared from malignant 
tissue compared to normal or benign, while middle- and 
opposite arm-derived sdRNAs were present only at very 
low read-counts in all libraries (Supplementary Figure 9a 
and 10). 
SNORD78 and sd78-3’ expression is associated 
with metastatic PCa
To validate our sequencing data we tested the 
expression of SNORD44, SNORD78, SNORD74, 
SNORD81, and their derivate sdRNAs, in an independent 
patient cohort of 106 fresh-frozen clinical samples 
by quantitative real-time PCR (Q-PCR). To evaluate 
whether increased sdRNA expression is a result of a 
general activation of the GAS5 locus, we also measured 
the expression of the spliced GAS5 transcript (Figure 
6 and Supplementary Figure 9b). All tested snoRNAs 
and sdRNAs were upregulated in organ-confined PCa 
compared to normal adjacent controls. This was not 
related to an elevation of the spliced GAS5 transcript, 
which did not demonstrate pronounced expression changes 
between NAP and PCa. Interestingly, overlapping sdRNAs 
originating from the same snoRNA as well as full-length 
snoRNAs were simultaneously detectable by Q-PCR 
suggesting the existence of multiple conformational states 
of these snoRNAs. 
Sd78-3’, SNORD78 and GAS5 expression was also 
detectable in different normal basal prostate epithelium 
cell lines (PNT2C2, RWPE) prostate cancer cell lines 
(PC346C, LAPC4, VCAP, LNCAP, 22RV1, PC3, 
and DU145N) as well as in hepatocellular carcinoma 
(HEP3B) and colon adenocarcinoma (COLO205) cells 
demonstrating that SNORD78 processing to sd78-3’ is not 
restricted to prostate tissue or cells. Similarly to patient 
data, the expression levels of sd78-3’ and SNORD78 were 
not correlated to the expression of the GAS5 host gene 
(Supplementary Figure 11).
Consistent with our previous results [3] sd78-3’ 
was upregulated in the LN library generated in this study, 
suggesting association of this sdRNA with aggressive 
disease. Therefore, in the validation cohort we stratified 
patients with organ-confined disease at the time of radical 
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Figure 4: Global processing patterns and relative abundance of sdRNAs and miRNAs expressed in prostate (cancer) 
tissues. (a) Full-length C/D-box snoRNAs are aligned relative to the middle nucleotide of each sequence. (b) H/ACA-box snoRNAs are 
aligned based on the position of the H-box. (c) Pre-miRNAs are aligned relative to the middle nucleotide of each sequence. A green line 
represents each full-length sncRNA. Sequences are extended 10 nt at each end to avoid mapping ambiguity caused by incorect annotation. 
Positions of detected conserved H/ACA-boxes or C/D-boxes are shown in blue and red. Light and dark grey lines indicate the positional 
origin of sdRNAs, miRNAs and miRNAs*. The color intensity corresponds to the relative abundance of sncdRNAs originating from the 
same precursor (read-count as a percentage of the total read-count per precursor), e.g. if only one sdRNA per snoRNA-precursor is detected 
it is assigned 100% abundance, if two or more sdRNAs originate from the same snoRNA the sdRNA with the highest read-count is given 
the darkest color and the sdRNA with the lowest read-count - the lightest. Thin dashed lines separate each panel into three subgroups where 
sncRNAs producing only one sncdRNA are on top, sncRNAs producing two sncdRNAs are in the middle and those producing there or more 
sncdRNAs are on the bottom. The highly sequentially conserved, multiple gene-copy C/D-box snoRNAs from the SNORD116 (HBII-85) 
and SNORD115 (HBII-52) families are grouped together below other C/D-box snoRNAs. The X-axis indicates the position of sncdRNAs 
relative to the center of their precursor sequence. The Y-axis depicts the number of full-length sncRNA precursors.
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Figure 5: Genomic organization, conservation, secondary folding, fragmentation pattern and expression of SNORD44, 
SNORD74, SNORD78, and SNORD81. (a) SNORD44, SNORD74, SNORD78, and SNORD81 are transcribed simultaneously from 
the conserved intronic regions of the protein-non-coding GAS5 gene. Spliced exons (boxes); snoRNA loci (arrows). (b) sdRNAs from 
SNORD44, SNORD74, SNORD78, and SNORD81 are up-regulated in PCa. Expression is comparable to PCa-relevant microRNA (not 
shown). SNORD74 and SNORD81 produce equally expressed 5’- (sd5’), middle- (sdM), and 3’-sdRNAs (sd3’) with overlapping sdM 
and sd3’. SdRNAs originating from the middle regions extend towards the antisense box and their 5’-ends map exactly adjacent to the 
nucleotide complementary to the targeted ribosomal residue. (c) SNORD44 and SNORD78 produce predominantly one sdRNA either from 
the 5’- or the 3’-arm of the snoRNA. The position of core snoRNP-proteins NOP58/56 and FIBRILLARIN (indicated at SNORD74) is 
dependent on the kink-turns formed by non-complementary base-pairing (dots) of the conserved external sequence boxes C and D and/
or the internal boxes C’/D’. The rRNA-complementary antisense-box (lower case) is exposed and contains the nucleotide targeted for 
modification (red), positioned exactly 5 nt upstream of the D or D’ box.
Figure 6: Q-PCR validation of snoRNA and sdRNA expression in an independent cohort of patient samples. NAP, normal 
adjacent prostate (n=17); PCa-cured, radical prostatectomy sample, no disease relapse after radical prostatectomy (n=20); PCa-biochem, 
radical prostatectomy sample, patients manifested biochemical disease relapse after surgery (n=18); PCa-met, radical prostatectomy sample, 
metastatic disease progression after surgery (n=10); LN-normal, normal lymph node (n=3); LN-PCa, metastatic lymph node (n=11); TURP-
normal, transurethral resection of the prostate sample that does not contain cancer cells (n=3). PCa-TURP, transurethral resection of the 
prostate sample that contains cancer cells (n=24). Horizontal line marks the mean of each group. Patient number in each group is indicated 
in brackets. P-values from unpaired two-tailed t-tests (alpha level 0.05) are indicated above each comparison.
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prostatectomy into three groups: cured after radical 
prostatectomy, biochemical disease reoccurrence, and 
progression to metastatic disease after surgery. Strikingly, 
the expression of sd78-3’ and its precursor SNORD78 
in the third group was significantly higher already at the 
time of surgery, suggesting an early involvement in PCa 
progression and possible prognostic marker potential for 
these sncRNAs. 
DISCUSSION
SncRNAs and in particular miRNAs emerged as 
novel modulators of gene expression and regulators of 
fundamental cellular processes often disturbed in cancer. 
At the same time, long-known “housekeeping” RNAs such 
as snoRNAs appeared to have tissue-specific expression 
altered in solid tumors and hematological malignances 
[8, 36, 43]. Furthermore, several studies discussed above 
demonstrate that similarly to miRNA, snoRNAs carry 
diagnostic and/or prognostic biomarker potential in 
different cancer types [6-10, 14, 15]. 
Improved detection and screening over the last 
decade led to large increase in prostate cancer detection. 
However, the majority of presently diagnosed patients 
carry clinically insignificant tumors, which would never 
progress to a life threatening disease. Without the presence 
of better prognostic markers, many patients undergo 
unnecessary invasive surgical treatment. 
Prompted by our previous findings on elevated 
levels of snoRNA fragments in metastatic PCa [3] and 
by accumulating evidence from sequencing data that 
demonstrates processing of snoRNA to stable smaller 
sdRNAs [22, 32, 37] we combined RNA sequencing of 
human prostate (cancer) tissue with tailored computational 
analysis. This resulted in a methodologically quantitated 
catalog of 3927 sncdRNAs originating from 1637 unique 
sncRNAs and allowed us to follow for changes in their 
expression during malignant transformation and cancer 
progression. 
To investigate possible effects of sample storage 
conditions we compared the sncRNA transcriptome of 
fresh-frozen tissue with its FFPE-stored counterpart. We 
saw large changes in the accumulation of sncdRNAs, 
particularly sdRNAs and tRFs, when we compared 
fresh-frozen with FFPE material. This was not the case 
for miRNAs were we observed only relative down-
regulation most possibly caused by the additional buildup 
of degradation products of mRNAs and long ncRNAs due 
to sample preparation and storage [35]. In addition, while 
miRNA read-length in FFPE tissue remained unchanged, 
reads from other sncRNAs had changed length distribution 
indicating that FFPE-preserved tissue is less suitable for 
the analysis of sncRNAs other than miRNA.
Previously we detected differential expression 
of sdRNAs between organ-confined PCa and lymph 
node metastases [3]. The expression analysis presented 
here indicates that the major accumulation of sdRNAs 
is associated with malignant transformation and can 
be described by an increased global production and/
or accumulation of sdRNAs already in the early cancer 
stages but it is not directly associated with the expression 
levels of precursor snoRNAs. Biological replicate analysis 
among three libraries (PCa, Gleason score 6) confirms the 
reproducibility of sequencing experiments on fresh-frozen 
tissue as less than 20 sncRNAs show significantly changed 
expression levels. We did not observe a direct association 
between the number of sncdRNAs arising from one 
precursor and its quantity suggesting that sncdRNA 
accumulation is not the direct result of increased sncRNA 
turnover in malignant cells. Q-PCR analysis confirmed 
the expression changes detected by sequencing and 
also identified the simultaneous existence of full-length 
snoRNAs and their derivate sdRNAs from the GAS5 
locus. The high levels of SNORD78 and sd78-3’ in a 
subset of patients, which progressed to metastatic disease, 
identify these two sncRNAs as possible novel prognostic 
biomarkers for the further stratification of PCa patients at 
high risk of developing aggressive disease.
It has been shown that the majority of C/D-sdRNAs 
are derived from the termini of their precursor and may 
remain attached to the core snoRNP shielded from further 
degradation [28]. A large part of the sdRNAs detected in 
our libraries is also terminally derived. Nevertheless, the 
processing patterns of snoRNAs that we observe, and the 
accumulation of specific sdRNAs appear to be dependent 
on the conservation of structural snoRNA features and 
do not always correspond to snoRNA termini protected 
by the snoRNP. Furthermore, the overlap and discrete 
origin-position of multiple sdRNAs produced from the 
same precursor exemplified by sdRNAs produced from 
SNORD44, SNORD78, SNORD74 and SNORD81 suggest 
rather specific nucleolytic cleavage that requires different 
conformational states for C/D-box snoRNAs [44] possibly 
assisted by structural interaction with the core snoRNPs 
or yet unidentified proteins. Of note, the highly abundant 
sd78-3’ is derived from the opposite part of SNORD78 
and does not overlap with the previously reported snoRNP 
footprint of SNORD78 observed by Kishore et al [28]. It 
has been proposed that the specificity of sdRNA processing 
patterns detected in human cell lines is conserved between 
different cell types while the accumulation of individual 
sdRNAs is cell type specific implying the existence of 
dedicated processing mechanisms [22, 23, 32, 45]. 
It remains to be established how sdRNAs and other 
sncdRNAs are produced in the cell and to what extend this 
process is deregulated in cancer. The miRNA processing 
RNaseIII, DICER was suggested in the biogenesis of H/
ACA-box-originating sdRNAs that have an apparent size 
of 20-24 nt. However, C/D box-sdRNAs identified by 
us and others [22, 23] have a bimodal size distribution 
which deviates from that of Dicer products, suggesting 
the involvement of other nuclease(s) in the generation of 
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sdRNAs. Another protein from the miRNA biogenesis 
pathway that could be involved in the generation of 
SNORD-sdRNAs is AGO2. It has been shown that AGO2 
is responsible for the maturation of pre-miRNA-451 which 
is too short to undergo Dicer processing. The AGO2 
cleaved miR-451 product is a fragment of 30 nt that is 
processed further to the mature 23 nt long miR-451 by 
unknown exonucleases [46]. Nonetheless, AGO2-derived 
mature miR-451 is predominantly uridilated at is 3’-end, 
while most of the C/D box-sdRNAs in our libraries are 
not. Furthermore, recent analyses of AGO2 PAR-CLIP 
libraries demonstrate that despite their cellular abundance, 
C/D box snoRNAs-originating sdRNAs are not efficiently 
incorporated in AGO2 [28].
The small transcriptome is a mix of turnover 
products and functional entitles, where a proportion 
of the cellular sdRNA pool most probably represents 
stable degradation products shielded by effector proteins. 
Nevertheless, the mechanisms of sdRNA generation and 
their putative functional role in normal and malignant 
cells should be investigated further alongside with their 
biomarker potential in prostate and other cancers. 
MATERIALS AND METHODS
Patient samples and cell lines
Snap-frozen, liquid nitrogen stored and FFPE 
clinical samples (Supplementary Table 1) were from the 
tissue bank of the Erasmus University Medical Center, 
Rotterdam, The Netherlands and from Tampere University 
Hospital (TAUH), Tampere, Finland. Collection and 
use of patient material was performed according to the 
national legislations concerning ethical requirements and 
approved by the Erasmus MC Medical Ethics Committee, 
Medical Research Involving Human Subjects Act (MEC-
2004-261), and the Ethical Committee of the Tampere 
University Hospital. 
Prostate and lymph node tissues were from 
radical prostatectomy. BPH samples were obtained 
from cystoprostatectomies and found not to contain any 
prostate cancer cells. PCa-TURP samples were collected 
by transurethral resection of the prostate. Histological 
evaluation of analyzed material was described previously 
[3].
RNA isolation
Total RNA from frozen tissue was isolated using 
RNABee reagent (Campro Scientific, GmbH, Berlin, 
Germany) according to manufacturer’s protocols. Total 
RNA isolation from FFPE material was described 
previously [37]. 
Sequencing
Total RNA sample pools of four individual patient 
samples each, were outsourced (BGI, Shenzhen, China) 
for sequencing. Library preparations were performed 
according to the “Small RNA Sample Preparation Guide, 
Part #1004239”, (Illumina Inc., http://www.illumina.
com). Shortly, total RNA pools were separated on 15% 
Tris/Borate/EDTA urea polyacrylamide electrophoresis 
gel, and the sncRNA fraction in the size range of 15 to 
35 nt was extracted and purified. After 5’- and 3’-adapter 
ligation, cDNA was generated by reverse transcription 
with SuperScript II Reverse Transcriptase (Invitrogen, 
Carlsbad, CA, USA) followed by 15 cycles of PCR 
by Phusion DNA Polymerase (Finnzymes Oy, Espoo, 
Finland).
Small non-coding RNA database (sncRNAdb)
Official small non-coding RNA nomenclature lists 
and NCBI RefSeq identifier numbers for microRNA 
precursors (pre-miRNAs), small nucleolar RNAs 
(snoRNAs), small cytoplasmic RNA (scRNAs), small 
nuclear RNA (snRNAs), and small miscellaneous 
RNAs (miscRNAs) were retrieved from the HUGO 
Gene Nomenclature Committee (HGNC) (http://www.
genenames.org) [47]. Genome locations corresponding 
to the RefSeq entries were further extended with 10 nt 
at the 5’- and 3’-end to ensure correct mapping of reads 
derived from ambiguously annotated ncRNAs and mapped 
against the Human Genome Browser – hg19 assembly at 
the University of California Santa Cruz (UCSC) (http://
genome.ucsc.edu).[48] UCSC Genome Browser uses 
miRBase 15; therefore all miRNAs entries were manually 
curated to match miRBase 17. 
Since HGNC does not provide RefSeq identifiers 
for tRNAs, tRNA data was retrieved from the UCSC 
dedicated Genomic tRNA Database (http://gtrnadb.ucsc.
edu/) [49]. The number of mapped reads was positively 
influenced by the addition of “CCA” triplet to the 3’-
end of genomic tRNA sequences and intron removal. 
Therefore, tRNA entries represent the mature tRNA 
form and are not extended. Sequences, genomic loci and 
database identifiers of all ncRNAdb entries are given in 
Supplementary File 1). 
Computational analysis of sequencing data
Initial mapping of sequencing reads to sncRNAdb 
was done in CLC-Bio Genomics Workbench (v. 4.9) 
following the “Small RNA Analysis” workflow. Read-
summarizing and adapter-removal parameters from 
the “Extract and Count” tool were applied: Minimum 
sampling count was 4; Minimum and maximum number 
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of nucleotides in reads was 15 and 35 nt, respectively; no 
3’- or 5’- terminal nucleotide removal was performed. 
Each read was screened with “no fixed adapter length” 
for the (partial) presence of Illumina small RNA adapter: 
CAAGCAGAAGACGGCATACGA on the minus strand 
with alignment mismatches and gaps allowance at a 
mismatch cost of 3, and a gap cost of 5, minimum score: 
ns, minimum score end: 3. If adapter was not found reads 
were discarded from further analysis. Filtered sequence 
reads were mapped to sncRNAdb with a maximum of 2 
mismatches allowed using the “Annotate and Merge” tool. 
Location, annotation and quantitation of 
sncdRNAs
Annotation of sncdRNAs was done using 
FlaiMapper as described [38]. Only sequence reads 
from libraries derived from fresh-frozen material were 
used as an input for the calculation of 5’- and 3’-ends 
of sncdRNAs. Quantitation and expression analysis of 
sncdRNAs was performed in a second round of mapping 
to FlaiMapper annotated sncRNAdb using ‘Small RNA 
Analysis’ workflow in CLC-Bio Genomics Workbench 
(v.4.9). “Expression values” that equal the sum of all 
reads mapping to a FlaiMapper annotated sncdRNA were 
used. Expression data was normalized with the “Reads per 
Million” algorithm. Differentially expressed sncdRNAs 
were detected using Kal’s Z-test on proportions [50] with 
two-sided p-value, followed by Bonferroni correction with 
a corrected p-value cut-off of 0.01. 
Quantitative real time PCR (qPCR)
snoRNA and sdRNA expression levels were 
evaluated by qPCR using miRCURY LNA™ Universal RT 
microRNA PCR, Polyadenylation and cDNA synthesis and 
SYBR Green kits (Exiqon, Copenhagen, Denmark) and 
custom LNA™ primers according to the manufacturer’s 
instructions. Custom LNA primers for qPCR analysis of 
snoRNAs and sdRNAs were designed by Exoqon A/S, 
Copenhagen, Denmark. Target sequences used for primer 
design as well as design IDs are listed in Supplementary 
methods table M1. SNORD38B expression was measured 
with Reference gene primer set 20391 (Exiquon, Vedbaek, 
Denmark) and used to normalize raw Ct values by the 
delta delta Ct Method.
GAS5 expression was assessed by the Promega 
Reverse Transcription System (Promega Benelux, The 
Netherlands) and SybrGreen qPCR System (Roche, The 
Netherlands) according to manufacturer protocols. Primers 
used were GAS5 FW: CAAGGACTCAGAATTCATGAT 
and GAS5 REV: AGTGGTCTTTGTAGACTGCC. Raw 
expression values were normalized against the geometrical 
mean of GAPDH and PBGD by the delta delta Ct Method. 
Statistical analysis
Significance of sncRNA composition and 
read-numbers were assessed with chi-square test for 
independence without Yates’ correction. Two-sided 
p-values were calculated at alpha level of 0.05. Differences 
between groups in qPCR experiments were tested with 
unpaired two-tailed t-test at alpha level 0.05. Pearson 
correlation coefficients were assessed at an alpha level of 
0.05 using GraphPad Prism 5.
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